<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p150" style="overflow: hidden; position: relative; background-color: white; width: 935px; height: 1210px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_150{left:119px;bottom:1134px;letter-spacing:0.11px;word-spacing:0.02px;}
#t2_150{left:799px;bottom:1132px;letter-spacing:-0.08px;}
#t3_150{left:141px;bottom:1081px;letter-spacing:0.14px;}
#t4_150{left:162px;bottom:1060px;letter-spacing:0.14px;}
#t5_150{left:162px;bottom:1025px;letter-spacing:0.13px;word-spacing:0.03px;}
#t6_150{left:243px;bottom:1025px;letter-spacing:0.11px;word-spacing:0.02px;}
#t7_150{left:162px;bottom:1008px;letter-spacing:0.1px;word-spacing:0.02px;}
#t8_150{left:162px;bottom:972px;letter-spacing:0.12px;}
#t9_150{left:255px;bottom:972px;letter-spacing:0.12px;word-spacing:2.6px;}
#ta_150{left:162px;bottom:955px;letter-spacing:0.11px;word-spacing:0.64px;}
#tb_150{left:162px;bottom:937px;letter-spacing:0.12px;word-spacing:5.02px;}
#tc_150{left:162px;bottom:920px;letter-spacing:0.11px;word-spacing:0.02px;}
#td_150{left:162px;bottom:902px;letter-spacing:0.11px;word-spacing:-0.67px;}
#te_150{left:319px;bottom:902px;letter-spacing:0.11px;word-spacing:-0.68px;}
#tf_150{left:162px;bottom:884px;letter-spacing:0.11px;word-spacing:-0.88px;}
#tg_150{left:162px;bottom:867px;letter-spacing:0.12px;word-spacing:1.47px;}
#th_150{left:162px;bottom:850px;letter-spacing:0.12px;word-spacing:1.02px;}
#ti_150{left:162px;bottom:832px;letter-spacing:0.1px;word-spacing:0.03px;}
#tj_150{left:162px;bottom:814px;letter-spacing:0.12px;}
#tk_150{left:215px;bottom:814px;letter-spacing:0.12px;word-spacing:4.36px;}
#tl_150{left:162px;bottom:797px;letter-spacing:0.12px;word-spacing:-0.06px;}
#tm_150{left:162px;bottom:779px;letter-spacing:0.11px;word-spacing:0.95px;}
#tn_150{left:162px;bottom:762px;letter-spacing:0.11px;word-spacing:1.04px;}
#to_150{left:162px;bottom:744px;letter-spacing:0.11px;word-spacing:0.02px;}
#tp_150{left:162px;bottom:726px;letter-spacing:0.11px;word-spacing:-0.39px;}
#tq_150{left:346px;bottom:726px;letter-spacing:0.11px;word-spacing:-0.37px;}
#tr_150{left:162px;bottom:709px;letter-spacing:0.11px;word-spacing:-0.04px;}
#ts_150{left:162px;bottom:691px;letter-spacing:0.12px;word-spacing:1.35px;}
#tt_150{left:162px;bottom:674px;letter-spacing:0.11px;word-spacing:0.03px;}
#tu_150{left:162px;bottom:656px;letter-spacing:0.13px;}
#tv_150{left:297px;bottom:656px;letter-spacing:0.11px;word-spacing:-0.4px;}
#tw_150{left:162px;bottom:639px;letter-spacing:0.1px;word-spacing:0.39px;}
#tx_150{left:162px;bottom:621px;letter-spacing:0.11px;word-spacing:0.02px;}
#ty_150{left:141px;bottom:564px;letter-spacing:0.14px;}
#tz_150{left:162px;bottom:543px;letter-spacing:0.13px;}
#t10_150{left:162px;bottom:509px;letter-spacing:0.14px;word-spacing:0.03px;}
#t11_150{left:275px;bottom:509px;letter-spacing:0.1px;word-spacing:0.03px;}
#t12_150{left:162px;bottom:491px;letter-spacing:0.11px;word-spacing:-0.33px;}
#t13_150{left:162px;bottom:473px;letter-spacing:0.11px;word-spacing:0.03px;}
#t14_150{left:162px;bottom:438px;letter-spacing:0.11px;word-spacing:0.94px;}
#t15_150{left:162px;bottom:421px;letter-spacing:0.11px;word-spacing:-0.5px;}
#t16_150{left:162px;bottom:403px;letter-spacing:0.1px;word-spacing:0.23px;}
#t17_150{left:162px;bottom:386px;letter-spacing:0.11px;word-spacing:1.06px;}
#t18_150{left:162px;bottom:368px;letter-spacing:0.1px;word-spacing:-0.8px;}
#t19_150{left:162px;bottom:351px;letter-spacing:0.11px;word-spacing:0.95px;}
#t1a_150{left:162px;bottom:333px;letter-spacing:0.12px;word-spacing:2.62px;}
#t1b_150{left:162px;bottom:315px;letter-spacing:0.11px;word-spacing:-0.71px;}
#t1c_150{left:162px;bottom:298px;letter-spacing:0.12px;word-spacing:5.49px;}
#t1d_150{left:162px;bottom:280px;letter-spacing:0.11px;word-spacing:1.94px;}
#t1e_150{left:162px;bottom:263px;letter-spacing:0.1px;word-spacing:-0.39px;}
#t1f_150{left:162px;bottom:245px;letter-spacing:0.11px;word-spacing:0.65px;}
#t1g_150{left:162px;bottom:227px;letter-spacing:0.12px;word-spacing:2.45px;}
#t1h_150{left:162px;bottom:210px;letter-spacing:0.12px;word-spacing:3.97px;}
#t1i_150{left:162px;bottom:193px;letter-spacing:0.11px;word-spacing:0.03px;}

.s0_150{font-size:15px;font-family:TimesNewRomanPSMT_6e;color:#000;}
.s1_150{font-size:17px;font-family:Calibri_7k;color:#000;}
.s2_150{font-size:18px;font-family:TimesNewRomanPS-BoldMT_7w;color:#000;}
.s3_150{font-size:15px;font-family:TimesNewRomanPS-BoldMT_7s;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts150" type="text/css" >

@font-face {
	font-family: Calibri_7k;
	src: url("fonts/Calibri_7k.woff") format("woff");
}

@font-face {
	font-family: TimesNewRomanPS-BoldMT_7s;
	src: url("fonts/TimesNewRomanPS-BoldMT_7s.woff") format("woff");
}

@font-face {
	font-family: TimesNewRomanPS-BoldMT_7w;
	src: url("fonts/TimesNewRomanPS-BoldMT_7w.woff") format("woff");
}

@font-face {
	font-family: TimesNewRomanPSMT_6e;
	src: url("fonts/TimesNewRomanPSMT_6e.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg150Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg150" style="-webkit-user-select: none;"><object width="935" height="1210" data="150/150.svg" type="image/svg+xml" id="pdf150" style="width:935px; height:1210px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_150" class="t s0_150">Brain: Chemistry to Cognition </span><span id="t2_150" class="t s1_150">142 </span>
<span id="t3_150" class="t s2_150">P110: Exploring the relationship of hyperhomocysteinemia with executive functioning </span>
<span id="t4_150" class="t s2_150">in older adults </span>
<span id="t5_150" class="t s3_150">Sandhya G, </span><span id="t6_150" class="t s0_150">Palash Kumar Malo, TLSA study team, Thomas Gregor Issac </span>
<span id="t7_150" class="t s0_150">Centre for Brain Research, Indian Institute of Science </span>
<span id="t8_150" class="t s3_150">Background: </span><span id="t9_150" class="t s0_150">Hyperhomocysteinemia (HHcy) is a known risk factor for cardiovascular diseases. Since </span>
<span id="ta_150" class="t s0_150">dementia more often involves cerebrovascular pathology, it becomes important to study homocysteine as a </span>
<span id="tb_150" class="t s0_150">potential risk factor for cognitive impairment. The current study aims to examine whether plasma </span>
<span id="tc_150" class="t s0_150">homocysteine levels affect cognitive performance especially executive functioning in older adults. </span>
<span id="td_150" class="t s3_150">Materials and methods: </span><span id="te_150" class="t s0_150">This study used baseline data from CBR-Tata Longitudinal Study of Ageing (CBR- </span>
<span id="tf_150" class="t s0_150">TLSA). Participants were assessed for cognitive performance and executive functioning using Addenbrooke's </span>
<span id="tg_150" class="t s0_150">Cognitive Examination-III (ACE-III) and Trail Making Test-B (TMT-B) respectively. Homocysteine was </span>
<span id="th_150" class="t s0_150">quantified using chemiluminescence immunoassays. Mann-Whitney U test was used to compare means of </span>
<span id="ti_150" class="t s0_150">scores between groups. </span>
<span id="tj_150" class="t s3_150">Results:</span><span id="tk_150" class="t s0_150">1212 participants were stratified into three groups based on age (45-54, 55-64, ≥65 years). </span>
<span id="tl_150" class="t s0_150">Homocysteine levels higher than median 17.22µmol/L were considered HHcy. People ≥65 years with HHcy </span>
<span id="tm_150" class="t s0_150">had significantly lower ACE-III than people without HHcy of same age group (p=0.005). Further analysis </span>
<span id="tn_150" class="t s0_150">showed that only women ≥65 years of age had significant difference among HHcy groups (p=0.014). The </span>
<span id="to_150" class="t s0_150">scores in TMT-B did not show differences with HHcy across all age groups and genders (p&gt;0.05). </span>
<span id="tp_150" class="t s3_150">Discussion and conclusions: </span><span id="tq_150" class="t s0_150">The present study showed that, in women ≥ 65 years of age, people with HHcy </span>
<span id="tr_150" class="t s0_150">scored significantly lesser in ACE-III than those without HHcy. The observed result might be due to uneven </span>
<span id="ts_150" class="t s0_150">prevalence of HHcy among the genders and the post-menopause effects in women. But such a difference </span>
<span id="tt_150" class="t s0_150">among people with different HHcy status was not observed in TMT-B. </span>
<span id="tu_150" class="t s3_150">Acknowledgements: </span><span id="tv_150" class="t s0_150">I would like to thank the CBR-TLSA study team who were involved in data collection. </span>
<span id="tw_150" class="t s0_150">I would also thank the participants of the study for their active participation and cooperation. I also express </span>
<span id="tx_150" class="t s0_150">my gratitude to Tata Trusts and Centre for Brain Research for funding the research. </span>
<span id="ty_150" class="t s2_150">P111: Development of novel therapeutics for mitigation of burn injury-induced chronic </span>
<span id="tz_150" class="t s2_150">pain </span>
<span id="t10_150" class="t s3_150">Sangam Barnwal</span><span id="t11_150" class="t s0_150">, Vinod Tiwari </span>
<span id="t12_150" class="t s0_150">Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology., Banaras Hindu </span>
<span id="t13_150" class="t s0_150">University, Varanasi-221005 </span>
<span id="t14_150" class="t s0_150">Burn injuries are among the underappreciated injuries associated with substantial morbidity and mortality. </span>
<span id="t15_150" class="t s0_150">Burn injuries, particularly severe burns are accompanied by an immune ad inflammatory response, metabolic </span>
<span id="t16_150" class="t s0_150">changes, and distributive shock that can be challenging to manage and can lead to multiple organ failure. In </span>
<span id="t17_150" class="t s0_150">India, over 100,000,0 people are moderately or severely burnt every year. Burns not only lead to physical </span>
<span id="t18_150" class="t s0_150">trauma but also psychological trauma. Burn injury treatment follows a series of events such as wound healing, </span>
<span id="t19_150" class="t s0_150">suppression of chronic pain, and stabilizing the proinflammatory cytokines. The major neuroinflammatory </span>
<span id="t1a_150" class="t s0_150">mediators are starting from NGF, TRPVI to NR2B, and some voltage-gated ion channels. This further </span>
<span id="t1b_150" class="t s0_150">activates PKA/PKC pathway, increases the influx of Na+ ions as well as Ca+2; sensitizes the AMPA channel, </span>
<span id="t1c_150" class="t s0_150">and simultaneously microglial activation. Current therapeutics are morphine and its analogs, some </span>
<span id="t1d_150" class="t s0_150">antipsychotic drugs, and antiepileptic drug but all of them have their own limitations like CNS toxicity. </span>
<span id="t1e_150" class="t s0_150">Amiloride is a reversible blocker of the Acid Sensitive Ion Channel (ASIC) and has been reported as a potent </span>
<span id="t1f_150" class="t s0_150">analgesic in CCI-induced pain, Bone cancer pain, Neuropathic pain, and Ulcerative colitis pain. Moreover, </span>
<span id="t1g_150" class="t s0_150">ASIC is colocalized with TRPV1 in DRG so we hypothesize to use ASIC as a target. So far we have </span>
<span id="t1h_150" class="t s0_150">performed Evoked pain behavior studies and Biochemical; further, we are going to quantify mRNA </span>
<span id="t1i_150" class="t s0_150">expression ASIC and its protein concentration in DRG. </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
